-
Aihara H, Takasaki T, Toyosaki-Maeda T, Suzuki R, Okuno Y, Kurane I, 2000: T-cell activation and induction of antibodies and memory T cells by immunization with inactivated Japanese encephalitis vaccine[J]. Viral Immunol, 13, 179-186. doi: 10.1089/vim.2000.13.179
-
Anderson K B, Gibbons R V, Edelman R, Eckels K H, Putnak R J, Innis B L, W S, 2011: Interference and Facilitation Between Dengue Serotypes in a Tetravalent Live Dengue Virus Vaccine Candidate[J]. J Infect Dis 204, 204, 442-450. doi: 10.1093/infdis/jir279
-
Arora U, Tyagi P, Swaminathan S, Khanna N, 2013: Virus-like particles displaying envelope domain Ⅲ of dengue virus type 2 induce virus-specific antibody response in mice[J]. Vaccine, 31, 873-878. doi: 10.1016/j.vaccine.2012.12.016
-
Bäck A T, Lundkvist Å, 2013: Dengue viruses -an overview[J]. Infect Ecol Epidemiol, 3, -.
-
Beckett C G, Tjaden J, Burgess T, Danko J R, Tamminga C, Simmons M, Wu S-J, Sun P, Kochel T, Raviprakash K, Hayes C G, Porter K R, 2011: Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial[J]. Vaccine, 29, 960-968. doi: 10.1016/j.vaccine.2010.11.050
-
Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyaratvej A, 1987: Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers[J]. Bull World Health Organ, 65, 189-195.
-
Bhatt S, Gething P W, Brady O J, Messina J P, Farlow A W, Moyes C L, Drake J M, Brownstein J S, Hoen A G, Sankoh O, Myers M F, George D B, Jaenisch T, Wint G R W, Simmons C P, Scott T W, Farrar J J, Hay S I, 2013: The global distribution and burden of dengue[J]. Nature, 496, 504-507. doi: 10.1038/nature12060
-
Blaney J E, Hanson C T, Firestone C Y, Hanley K A, Whitehead S S, 2004a: Genetically modified, live attenuated dengue virus type 3 vaccine candidates[J]. Am J Trop Med Hyg, 71, 811-821.
-
Blaney J E, Hanson C T, Hanley K A, Murphy B R, Whitehead S S, 2004b: Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2[J]. BMC Infect Dis, 4, 39-. doi: 10.1186/1471-2334-4-39
-
Blaney J E, Sathe N S, Goddard L, Hanson C T, Romero T A, Hanley K A, Murphy B R, Whitehead S S, 2008: Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3'untranslated region (3'UTR) or by exchange of the DENV-3 3'UTR with that of DENV-4[J]. Vaccine, 26, 817-828. doi: 10.1016/j.vaccine.2007.11.082
-
Brinton M A, Fernandez A V, Dispoto J H, 1986: The 3'-nucleotides of flavivirus genomic RNA form a conserved secondary structure[J]. Virology, 153, 113-121. doi: 10.1016/0042-6822(86)90012-7
-
Capeding R Z, Luna I A, Bomasang E, Lupisan S, Lang J, 2011: Liveattenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase Ⅰ trial in the Philippines[J]. Vaccine, 29, 3863-3872. doi: 10.1016/j.vaccine.2011.03.057
-
Clements D E, Coller B A, Lieberman M M, Ogata S, Wang G, Harada K E, 2010: Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys[J]. Vaccine, 28, 2705-2715. doi: 10.1016/j.vaccine.2010.01.022
-
Coller B A G, Clements D E, Bett A J, Sagar S L, Meulen J H T, 2011: The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease[J]. Vaccine, 29, 7267-7275. doi: 10.1016/j.vaccine.2011.07.021
-
Durbin A P, Whitehead S S, 2010: Dengue Vaccine Candidates in Development[J]. Curr Top Microbiol Immunol, 338, 129-143.
-
Durbin A P, Kirkpatrick B D, Pierce K K, Schmidt A C, Whitehead S S, 2011: Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine[J]. Vaccine, 29, 7242-7250. doi: 10.1016/j.vaccine.2011.07.023
-
Durbin A P, Whitehead S S, McArthu r J, Perreault J R, Blaney J E, Thumar B, 2005: rDEN4 Delta 30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers[J]. J Infect Dis, 191, 710-718. doi: 10.1086/427780
-
Durbin A P, McArthur J H, Marron J A, Blaney J E, Thumar B, Wanionek K, 2006: rDEN2/4Delta30 (ME), A Live Attenuated Chimeric Dengue Serotype 2 Vaccine Is Safe and Highly Immunogenic in Healthy Dengue-Naive Adults[J]. Hum Vaccin, 2, 255-260. doi: 10.4161/hv.2.6.3494
-
Durbin A P, Karron R A, Sun W, Vaughn D W, Reynolds M J, Murphy B R, Whitehead S S, 2001: Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region[J]. Am J Trop Med Hyg, 65, 405-413. doi: 10.4269/ajtmh.2001.65.405
-
Garçon N, Van Mechelen M, 2011: Recent clinical experience with vaccines using MPL-and QS-21-containing Adjuvant Systems[J]. Expert Rev Vaccines, 10, 471-486. doi: 10.1586/erv.11.29
-
Garçon N, Wettendorff M, Van Mechelen M, 2011: Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile[J]. Expert Opin Biol Ther, 11, 667-677. doi: 10.1517/14712598.2011.573624
-
Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, Yoksan S, Duan X, Ermak T H, Kanesa-thasan N, Bedford P, Lang J, Quentin-Millet M-J, Monath T P, 2006: Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase Ⅰ clinical trial for safety and immunogenicity: effect of yellow fever preimmunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes[J]. Hum Vaccin, 2, 60-67. doi: 10.4161/hv.2.2.2555
-
Guy B, Saville M, Lang J, 2010: Development of Sanofi Pasteur tetravalent dengue vaccine[J]. Hum Vaccin, 6, 696-705. doi: 10.4161/hv.6.9.12739
-
Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M, 2008: Cellmediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects[J]. Vaccine, 26, 12-21. doi: 10.1016/j.vaccine.2007.11.068
-
Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J, 2011: From esearch to phase Ⅲ: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine[J]. Vaccine, 29, 7229-7241. doi: 10.1016/j.vaccine.2011.06.094
-
Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Dumas R, Lang J, 2009: Evaluation of Interferences between Dengue Vaccine Serotypes in a Monkey Model[J]. Am J Trop Med Hyg, 80, 302-311.
-
Guzman M G, Harris E, 2014: Dengue[J]. The Lancet, Epub ahead of print, , -. doi: 10.1016/S0140-6736(14)60572-9
-
Guzman M G, Halstead S B, Artsob H, Buchy P, Farrar J, Gubler D J, Hunsperger E, Kroeger A, Margolis H S, Martínez E, Nathan M B, Pelegrino J L, Simmons C, Yoksan S, Peeling R W, 2010: Dengue: a continuing global threat[J]. Nat Rev Microbiol, 8, S7-S16. doi: 10.1038/nrmicro2460
-
Halstead S B, 1978: Studies on the attenuation of dengue 4[J]. Asian J Infect Dis, 2, 112-117.
-
Halstead S B, 2012: Controversies in dengue pathogenesis[J]. Paediatr Int Child H, 32, 5-9. doi: 10.1179/2046904712Z.00000000045
-
Halstead S B, Heinz F X, Barrett A D T, Roehrig J T, 2005: Dengue virus: molecular basis of cell entry and pathogenesis 25-27 June 2003, Vienna, Austria[J]. Vaccine, 23, 849-856. doi: 10.1016/j.vaccine.2004.03.069
-
Halstead S B, Durbin A P, Whitehead S S, Shaffer D, Elwood D, Wanionek K, Thumar B, Blaney J E, Murphy B R, Schmidt A C, 2011: A Single Dose of the DENV-1 Candidate Vaccine rDEN130 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial[J]. PLOS Negl Trop Dis, 5, e1267-. doi: 10.1371/journal.pntd.0001267
-
Hanley K A, Lee J J, Blaney J E, Murphy B R, Whitehead S S, 2002: Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes[J]. J Virol, 76, 525-531. doi: 10.1128/JVI.76.2.525-531.2002
-
Harenberg A, Begue S, Mamessier A, Caillet C, Guy B, 2013: Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore[J]. Hum Vacc Immunother, 9, 2317-2325. doi: 10.4161/hv.25562
-
Huang C Y, Butrapet S, Tsuchiya K R, Bhamarapravati N, Gubler D J, Kinney R M, 2003: Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development[J]. J Virol, 77, 11436-11447. doi: 10.1128/JVI.77.21.11436-11447.2003
-
Huang C Y, Kinney R M, Livengood J A, Bolling B, Osorio J E, Stinchcomb D T, 2013: Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax)[J]. PLOS Negl Trop Dis, 7, e2243-. doi: 10.1371/journal.pntd.0002243
-
Hui Lu, XiaoFeng Xu, Na Gao, An J, 2013: Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: Their immunity and protective efficacy in mice[J]. Mol Immunology, 54, 109-114. doi: 10.1016/j.molimm.2012.11.007
-
Innis B L, Eckels K H, 2003: Progress in development of a liveattenuated, tetravalent dengue virus vaccine by theUnited States Army Medical Research and Materiel Command[J]. Am J Trop Med Hyg, 69, 1-4.
-
Kitchener S, Nissen M, Nasveld P, Forrat R, Saluzzo J F, 2006: Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults[J]. Vaccine, 24, 1238-1241. doi: 10.1016/j.vaccine.2005.09.029
-
Lang J, 2012: Development of Sanofi Pasteur tetravalent dengue vaccine[J]. Rev Inst Med Trop Sao Paulo, 54, S15-S17. doi: 10.1590/S0036-46652012000700007
-
Leo Y S, Wilder-Smith A, Archuleta S, Shek L P, Chong C Y, 2012: Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 years Phase Ⅱ randomized controlled trial in Singapore[J]. Hum Vacc Immunother, 8, 1259-1271. doi: 10.4161/hv.21224
-
Letson G W, Singhasivanon P, Fernandez E, Abeysinghe N, Amador J J, Margolis H S, Edelman R, 2010: Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas[J]. Human Vaccines, 6, 802-809. doi: 10.4161/hv.6.10.13018
-
Lu H, Xu X, Gao N, An J, 2013: Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: Their immunity and protective efficacy in mice[J]. Molecular Immunology, 54, 109-114. doi: 10.1016/j.molimm.2012.11.007
-
Mahoney R, Chocarro L, Southern J, Francis D P, Vose J, Margolis H, 2011: Dengue Vaccines Regulatory Pathways: A Report on Two Meetings with Regulators of Developing Countries[J]. PLoS Medicine, 8, e1000418-. doi: 10.1371/journal.pmed.1000418
-
Mani S, Tripathi L, Raut R, Tyagi P, Arora U, Barman T, Sood R, Galav A, Silva A D, Swaminathan S, 2013: Pichia pastoris-Expressed Dengue 2 Envelope Forms Virus-Like Particles without Pre-Membrane Protein and Induces High Titer Neutralizing Antibodies[J]. PLoS one, 8, e64595-. doi: 10.1371/journal.pone.0064595
-
McArthur J H, Durbin A P, Marron J A, Wanionek K A, Murphy B R, Whitehead S S, 2008: Phase Ⅰ Clinical Evaluation of rDEN4Δ30-200, 201: A Live Attenuated Dengue 4 Vaccine Candidate Designed for Decreased Hepatotoxicity[J]. Am J Trop Med Hyg, 79, 678-684.
-
McKeage K, Romanowski B, 2011: AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types[J]. Drugs, 71, 465-488.
-
McKenzie A, Watt M, Gittleson C, 2010: ISCOMATRIXTM vaccines: safety in human clinical studies[J]. Hum Vaccin, 6, 237-246. doi: 10.4161/hv.6.3.10754
-
Men R, Bray M, Clark D, Chanockrober M, Lai C-J, 1996: Dengue Type 4 Virus Mutants Containing Deletions in the 39 Noncoding Region of the RNA Genome: Analysis of Growth Restriction in Cell Culture and Altered Viremia Pattern and Immunogenicity in Rhesus Monkeys[J]. J Virol, 70, 3930-3937.
-
Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A, Chomez P, Gar?on N, Van M M, 2011: Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity[J]. Vaccine, 29, 2461-2473. doi: 10.1016/j.vaccine.2011.01.011
-
Normile D, 2013: Surprising New Dengue Virus Throws A Spanner in Disease Control Efforts[J]. Scinece, 342, 415-. doi: 10.1126/science.342.6157.415
-
Osorio J E, Brewoo J N, Silengo S J, Arguello J, Stinchcomb D T, 2011: Efficacy of a Tetravalent Chimeric Dengue Vaccine (DENVax) in Cynomolgus Macaques[J]. Am J Trop Med Hyg, 84, 978-987. doi: 10.4269/ajtmh.2011.10-0592
-
Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan G H, 2011: Live-attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents, and adults in mexico city: randomized controlled phase 1 trial of safety and immunogenicity[J]. Pediatr Infect Dis J, 30, e9-17. doi: 10.1097/INF.0b013e3181fe05af
-
Putnak R, Barvir D A, Burrous J M, Dubois D R, D'Andrea V M, Hoke C H, Sadoff J C, Eckels K H, 1996: Development of a Purified, Inactivated, Dengue-2 Virus Vaccine Prototype in Vero Cells: Immunogenicity and Protection in Mice and Rhesus Monkeys[J]. J Infect Dis, 174, 1176-1184. doi: 10.1093/infdis/174.6.1176
-
Raviprakash K, Porter K R, Kochel T J, Ewing D, Simmons M, Phillips I, 2000: Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques[J]. J Gen Virol, 81, 1659-1667. doi: 10.1099/0022-1317-81-7-1659
-
Robert Putnak J, Coller B A, Voss G, Vaughn D W, Clements D, Peters I, Bignami G, Houng H-S, Chen R C M, Barvir D A, Seriwatana J, Cayphas S, Garçon N, Gheysen D, Kanesa-thasan N, McDonell M, Humphreys T, Eckels K H, Prieels J-P, Innis B L, 2005: An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model[J]. Vaccine, 23, 4442-4452. doi: 10.1016/j.vaccine.2005.03.042
-
Rodriguez-Roche R, Gould E A, 2013: Understanding the Dengue Viruses and Progress towards Their Control[J]. BioMed Research International, 2013, 690835-.
-
Rothman A L, 2011: Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms[J]. Nat Rev Immunol, 11, 532-543. doi: 10.1038/nri3014
-
Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W, Jagsudee A, Saluzzo J F, Bhamarapravati N, 2002: Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses[J]. Am J Trop Med Hyg, 66, 264-272. doi: 10.4269/ajtmh.2002.66.264
-
Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel T A, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth N G, Lang J, 2012: Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial[J]. Lancet, 380, 1559-1567. doi: 10.1016/S0140-6736(12)61428-7
-
Sanchez V, Thomas G N, Tomlinson B, Chan P K S, Thomas G N, 2006: Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)[J]. Vaccine, 24, 4914-4926. doi: 10.1016/j.vaccine.2006.03.066
-
Sardesai N Y, Weiner D B, 2011: Electroporation delivery of DNA vaccines: prospects for success[J]. Curr Opin Immun, 23, 421-429. doi: 10.1016/j.coi.2011.03.008
-
Simmons C P, Chau T N, Thuy T T, Tuan N M, Hoang D M, Thien N T, 2007: Maternal antibody and viral factors in the pathogenesis of dengue virus in infants[J]. J Infect Dis, 196, 416-424. doi: 10.1086/519170
-
Simmons M, Burgess T, Lynch J, Putnak R, 2010: Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy[J]. Virology, 396, 280-288. doi: 10.1016/j.virol.2009.10.023
-
Sinha G, 2014: Sanofi's dengue vaccine first to complete phase 3[J]. Nat Biotech, 32, 605-606.
-
Sun W, Nisalak A, Gettayacamin M, Eckels K H, Putnak J R, Vaughn D W, Innis B L, Thomas S J, Endy T P, 2006: Protection of Rhesus Monkeys against Dengue Virus Challenge following Tetravalent Live-attenuated Dengue Virus Vaccination[J]. J Inf Dis, 193, 1658-1665. doi: 10.1086/503372
-
Sun W, Cunningham D, Wasserman S S, Perry J, Putnak J R, Eckels K H, Vaughn D W, Thomas S J, Kanesa-Thasan N, Innis B L, Edelman R, 2009: Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults[J]. Hum Vaccin, 5, 33-40. doi: 10.4161/hv.5.1.6348
-
Thisyakorn U, Thisyakorn C, 2014: Latest developments and future direction in dengue vaccines[J]. Ther Adv Vacc, 2, 3-9. doi: 10.1177/2051013613507862
-
Thomas S J, 2011: The necessity and quandaries of dengue vaccine development[J]. J Infect Dis, 203, 299-303. doi: 10.1093/infdis/jiq060
-
Thomas S J, Endy T P, 2011: Critical issues in dengue vaccine development[J]. Curr Opin Infect Dis, 24, 442-450. doi: 10.1097/QCO.0b013e32834a1b0b
-
Thomas S J, Eckels K H, Carletti I, Gibbons R V, Innis B L, 2013: A Phase Ⅱ, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults[J]. Am J Trop Med Hyg, 88, 73-88. doi: 10.4269/ajtmh.2012.12-0361
-
Upasana Arora, Poornima Tyagi, Sathyamangalam Swaminathan, Khanna N, 2013: Virus-like particles displaying envelope domain Ⅲ of dengue virus type 2 induce virus-specific antibody response in mice[J]. Vaccine, 31, 873-878. doi: 10.1016/j.vaccine.2012.12.016
-
Valdés I, Hermida L, Gil L, Lazo L, Castro J, Martín J, Bernardo L, López C, Niebla O, Menéndez T, Romero Y, Sánchez J, Guzmán M G, Guillén G, 2010: Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use[J]. Int J Infect Dis, 14, e377-e383.
-
Valdés I, Hermida L, Martín J, Menéndez T, Gil L, Lazo L, Castro J, Niebla O, López C, Bernardo L, Sánchez J, Romero Y, Martínez R, Guzmán M G, Guillén G, 2009a: Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain Ⅲ of dengue 2 and two components of Neisseria meningitidis[J]. Vaccine, 27, 995-1001. doi: 10.1016/j.vaccine.2008.11.106
-
Valdés I, Bernardo L, Gil L, Pavón A, Lazo L, López C, Romero Y, Menendez I, Falcón V, Betancourt L, Martín J, Chinea G, Silva R, Guzmán M G, Guillén G, Hermida L, 2009b: A novel fusion protein domain Ⅲ-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice[J]. Virology, 394, 249-258. doi: 10.1016/j.virol.2009.08.029
-
Valdes I, Gil L, Romero Y, Castro J, Puente P, Lazo L, Marcos E, Guzman M G, Guillen G, Hermida L, 2011: The Chimeric Protein Domain Ⅲ-Capsid of Dengue Virus Serotype 2 (DEN-2) Successfully Boosts Neutralizing Antibodies Generated in Monkeys upon Infection with DEN-2[J]. Clin Vac Immun, 18, 455-459. doi: 10.1128/CVI.00382-10
-
Van der Straten A, Johansen H, Rosenberg M, Sweet R W, 1989: Introduction and constitutive expression of gene products in cultured drosophila cells using hygromycin B selection[J]. Meth Mol Cell Biol, 1, 1-8. doi: 10.1091/mbc.1.1.1
-
Villar L, Dayan G H, Arredondo-García J L, Saville M, Noriega F, 2014: Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America[J]. N Engl J Med. Epub ahead of print, , -. doi: 10.1056/NEJMoa1411037
-
Voelker R, 2010: Race Is On for Effective Dengue Vaccine[J]. JAMA, 304, -.
-
Wahala M P B, Silva A M d, 2011: The Human Antibody Response to Dengue Virus Infection[J]. Viruses, 3, 2374-2395. doi: 10.3390/v3122374
-
Wan S W, Lin C F, Wang S, Chen Y H, Yeh T M, Liu H S, Anderson R, Lin Y S, 2013: Current progress in dengue vaccines[J]. J Biomed Sci, 20, 37-. doi: 10.1186/1423-0127-20-37
-
Whitehead S S, Hanley K A, Jr. B J E, Gilmore L E, Elkins W R, Murphy B R, 2003: Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys[J]. Vaccine, 21, 4307-4316. doi: 10.1016/S0264-410X(03)00488-2
-
Whitehead S S, Falgout B, Hanley K A, Blaney J E, Markoff L, Murphy B R, 2003: A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys[J]. J Virol, 77, 1653-1657. doi: 10.1128/JVI.77.2.1653-1657.2003
-
Wright P F, Durbin A P, Whitehead S S, Ikizler M R, Henderson S, Blaney J E, 2009: Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers[J]. Am J Trop Med Hyg, 81, 834-841. doi: 10.4269/ajtmh.2009.09-0131
-
Zheng Q, Fan D, Gao N, An J, 2011: Evaluation of a DNA vaccine candidate expressing prM-E-NS1antigens of dengue virus serotype1with or without granulocyte-macrophagecolony-stimulating factor (GM-CSF) in immunogenicity and protection[J]. Vaccine, 29, 763-771. doi: 10.1016/j.vaccine.2010.11.014